Shen Zhao-Hua, Zeng Dong-Feng, Ma Ying-Ying, Zhang Xi, Zhang Cheng, Kong Pei-Yan
Department of Hematology, Xinqiao Hospital, The Third Military Medical University, Chongqing, 400037, People's Republic of China.
Med Oncol. 2015 Dec;32(12):262. doi: 10.1007/s12032-015-0705-9. Epub 2015 Nov 2.
AML is a common life-threatening blood system malignancy. The treatment of AML continues to face greater challenges. An abnormal haematopoietic niche with high adhesion and proliferation might be the root cause of resistance and relapse. Most leukaemia cells are stored in the endosteal niche and recess in the G0 phase, and they are not sensitive to varieties of radiotherapies and chemotherapies. G-CSF and AMD3100 are increasingly used in priming chemotherapy. G-CSF can promote leukaemia cells to the cell cycle, which improves the complete remission rate of leukaemia patients. AMD3100, the novel CXCR4 antagonist, could also potentially promote leukaemia cells to cell cycle and improve the susceptibility of leukaemia cells to chemotherapeutic agents. The combination of them enhances anti-leukaemia effect. So in this review, we explore the function of G-CSF and/or AMD3100 in the priming chemotherapy of haematological malignants.
急性髓系白血病（AML）是一种常见的危及生命的血液系统恶性肿瘤。AML的治疗仍然面临着更大的挑战。具有高黏附性和增殖性的异常造血微环境可能是耐药和复发的根本原因。大多数白血病细胞储存在骨内膜微环境中并处于G0期静止状态，它们对各种放疗和化疗不敏感。粒细胞集落刺激因子（G-CSF）和AMD3100越来越多地用于诱导化疗。G-CSF可促进白血病细胞进入细胞周期，从而提高白血病患者的完全缓解率。新型CXC趋化因子受体4（CXCR4）拮抗剂AMD3100也可能促进白血病细胞进入细胞周期，并提高白血病细胞对化疗药物的敏感性。它们联合使用可增强抗白血病效果。因此，在本综述中，我们探讨了G-CSF和/或AMD3100在血液系统恶性肿瘤诱导化疗中的作用。
